Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space

Executive Summary

• Onco-Innovations Limited announced its placement in a BioMedWire editorial titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology.”
• The editorial highlights the rapid expansion of DNA Damage Response inhibitors (DDRi) and positions the company’s lead asset, ONC010, as a nanoparticle-encapsulated PNKP inhibitor targeting solid tumors.
• The release serves as a routine communications update and does not disclose material corporate, financial, or clinical developments.

Key Details

• Publication Platform: BioMedWire (BMW), part of the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), syndicated to 5,000+ outlets with social media distribution and press release enhancement.
• Editorial Title: “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology”
• Market Context: DDRi therapies represented an estimated $7+ billion in global sales in 2025; the broader oncology, diagnostics, and precision medicine markets are projected to reach approximately $750 billion by 2030.
• Lead Asset: ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor targeting a DNA repair enzyme involved in multiple DNA repair pathways, positioned within the emerging wave of synthetic lethality assets.
• Company Profile: Canadian clinical-stage oncology company focused on cancer prevention and treatment, holding an exclusive worldwide license to patented technology targeting solid tumors.